var data={"title":"Dronabinol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dronabinol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6080?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dronabinol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dronabinol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=dronabinol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dronabinol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16116938\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Marinol;</li>\n      <li>Syndros</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163524\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Appetite Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163507\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Use caution when increasing the dose of dronabinol because of the increased frequency of dose-related adverse reactions at higher dosages.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anorexia in patients with AIDS:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: Initial: 2.5 mg twice daily (1 hour before lunch and dinner); for patients unable to tolerate this dosage, may reduce to 2.5 mg once daily (1 hour before dinner or at bedtime to reduce the risk of CNS symptoms). May increase dose gradually based on response and tolerability (maximum: 20 mg per day [in divided doses]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Initial: 2.1 mg twice daily (1 hour before lunch and dinner); although most patients respond to this dose, if further therapeutic effect is desired and if tolerated, may gradually increase to 2.1 mg 1 hour before lunch and 4.2 mg 1 hour before dinner, and then (if needed) to 4.2 mg twice daily (1 hour before lunch and dinner). Maximum: 16.8 mg per day [in 2 divided doses]. In patients unable to tolerate 2.1 mg twice daily, consider 2.1 mg once daily (1 hour before dinner or at bedtime) to reduce the risk of CNS effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting (manufacturer's labeling):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules: 5 mg/m<sup>2</sup> administered 1 to 3 hours before chemotherapy, then give 5 mg/m<sup>2</sup>/dose every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses/day; increase dose in increments of 2.5 mg/m<sup>2</sup> based on response and tolerability (maximum: 15 mg/m<sup>2</sup>/dose). Monitor for adverse reactions; consider reducing dose to 2.5 mg once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral solution: Initial: 4.2 mg/m<sup>2</sup> (rounded to the nearest 0.1 mg increment [or to the nearest 0.1 mL measurable increment on the calibrated oral dosing syringe]) 1 to 3 hours prior to chemotherapy and then every 2 to 4 hours after chemotherapy for a total of 4 to 6 doses/day. Titrate dose in 2.1 mg/m<sup>2</sup> increments (during a cycle or in subsequent cycles) to clinical response. Maximum: 12.6 mg/m<sup>2</sup>/dose and 4 to 6 doses/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting, refractory (off-label dosing):</b> Oral: Capsules: 2.5 to 10 mg 3 or 4 times daily (Lohr 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Obstructive sleep apnea, moderate to severe (off-label use):</b> Oral: 2.5 mg or 10 mg 1 hour before bedtime. An initial dose escalation is required for the 10 mg dose: Initiate at 2.5 mg 1 hour before bedtime for 7 days, followed by 5 mg 1 hour before bedtime for 7 days, and then 10 mg 1 hour before bedtime (Carley 2018).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163518\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=dronabinol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Dronabinol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Chemotherapy-induced nausea and vomiting: </b>Oral: Capsules: Refer to adult dosing. Use caution when increasing the dose because of the increased frequency of dose-related adverse reactions at higher dosages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163508\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anorexia in patients with AIDS:</b> Initial: Consider 2.5 mg once daily (1 hour before dinner or at bedtime) to reduce the risk of CNS symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting: </b>Initial: Consider 2.5 mg/m<sup>2</sup> once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS symptoms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anorexia in patients with AIDS:</b> Initial: Consider 2.1 mg once daily (1 hour before dinner or at bedtime) to reduce the risk of CNS effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting: </b>Initial: Consider 2.1 mg/m<sup>2</sup> once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS effects.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15804935\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163509\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48979126\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anorexia in patients with AIDS:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS adverse reactions: Reduce dose if needed. <b>Note:</b> Administering the dose later in the day may reduce the frequency of CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dizziness, somnolence, confusion, or euphoria: Adverse effects typically resolve within 1 to 3 days and usually do not require dose reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Severe or persistent CNS adverse effects: Reduce dose to 2.1 mg once daily 1 hour before dinner or in the evening at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">In patients unable to tolerate 2.1 mg twice daily, consider 2.1 mg once daily (1 hour before dinner or at bedtime) to reduce the risk of CNS effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CNS adverse reactions: Consider decreasing the dose to 2.1 mg once daily 1 to 3 hours prior to chemotherapy to reduce the risk of CNS adverse reactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163483\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Marinol: 2.5 mg, 5 mg, 10 mg [contains sesame oil]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Syndros: 5 mg/mL (30 mL) [contains alcohol, usp, methylparaben, polyethylene glycol, propylene glycol, propylparaben]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163466\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163526\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Marinol: C-III; Syndros: C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27750095\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsules:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anorexia in patients with AIDS: </b>Administer twice-daily doses 1 hour before lunch and dinner; administer single doses 1 hour before dinner or at bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting:</b> Administer the first dose on an empty stomach at least 30 minutes before eating; subsequent doses may be administered without regard to meals, although once titrated, the timing of administration in relation to meals should be kept consistent for each chemotherapy cycle.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Always use the provided calibrated oral dosing syringe when administering to ensure dose is measured and administered accurately. If the prescribed dose is &gt;5 mg, the total dose will need to be divided and drawn up in 2 or more portions using the oral syringe. Administer orally directly from oral dosing syringe; immediately follow with a full glass of water (180 to 240 mL).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anorexia in patients with AIDS:</b> Administer 1 hour before lunch and 1 hour before dinner initially; if persistent or severe CNS adverse effects occur, administering later in the day (1 hour before dinner and at bedtime) may reduce the frequency of CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting:</b> The first dose should be administered on an empty stomach at least 30 minutes prior to eating; subsequent doses within a chemotherapy cycle may be administered without regard to meals. Once a dose has been titrated, the timing of doses with regard to food in subsequent cycles should maintain consistency with prior cycles.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163485\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anorexia in patients with AIDS:</b> Treatment of anorexia associated with weight loss in patients with AIDS.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting:</b> Treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51128860\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Obstructive sleep apnea, moderate to severe</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163532\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Dronabinol may be confused with droperidol</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">To ensure accurate measuring and administration of dronabinol oral solution, always use the provided calibrated oral dosing syringe.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163473\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Central nervous system: Euphoria (antiemetic: 24%; appetite stimulant: 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Facial flushing (&gt;1%), palpitations (&gt;1%), tachycardia (&gt;1%), vasodilatation (&gt;1%), flushing (&le;1%), hypotension (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Abnormality in thinking (3% to 10%), dizziness (3% to 10%), drowsiness (3% to 10%), paranoia (3% to 10%), amnesia (&gt;1%), anxiety (&gt;1%), ataxia (&gt;1%), confusion (&gt;1%), depersonalization (&gt;1%), hallucination (&gt;1%), nervousness (&gt;1%), chills (&le;1%), depression (&le;1%), headache (&le;1%), malaise (&le;1%), nightmares (&le;1%), speech disturbance (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (3% to 10%), nausea (3% to 10%), vomiting (3% to 10%), anorexia (&le;1%), diarrhea (&le;1%), fecal incontinence (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased liver enzymes (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&gt;1%), myalgia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctival injection (&le;1%), conjunctivitis (&le;1%), visual disturbance (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Otic: Tinnitus (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&le;1%), rhinitis (&le;1%), sinusitis (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Burning sensation of skin, delirium, disorientation, exacerbation of depression, falling, fatigue, insomnia, loss of consciousness, mental status changes (exacerbation of mania or schizophrenia), movement disorder, oral lesion, panic attack, pharyngeal edema, seizure, skin rash, swelling of lips, syncope, urticaria, visual disturbance</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163488\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to dronabinol, sesame oil (capsules), alcohol (oral solution) or any component of the formulation; receiving, or have recently received, disulfiram- or metronidazole-containing products within 14 days (oral solution).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163470\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: May cause occasional hypotension, possible hypertension, syncope, or tachycardia; patients with cardiac disorders may be at higher risk for hemodynamic instability. Monitor for changes in heart rate, blood pressure, and for signs/symptoms of syncope after initiating treatment and with dosage increases. Avoid concomitant use with other medications associated with similar cardiovascular adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS adverse effects: Monitor for CNS adverse effects; may require dosage modification. Dronabinol has been reported to exacerbate depression, mania, or schizophrenia; screen patients for history of these conditions prior to treatment initiation. Significant CNS symptoms were associated with doses of 0.4 mg/kg in antiemetic studies. Avoid use in patients with a psychiatric history; if use cannot be avoided, monitor for new or worsening psychiatric symptoms. Avoid concomitant use with other medications associated with similar psychiatric adverse effects. May cause cognitive impairment, altered mental state, or CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery, driving). Elderly and pediatric patients may be more sensitive to neurologic and psychiatric effects of dronabinol. May require dose reduction or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; GI effects: New or worsening paradoxical nausea, vomiting, and/or abdominal pain may occur with synthetic cannabinoids; may be severe. Symptoms are similar to cannabinoid hyperemesis syndrome, which is a cyclical syndrome with the same symptoms occurring with long-term use of cannabinoid products. Monitor patients for specific related symptoms; development of worsening nausea, vomiting or abdominal pain may require dose reduction or discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including disseminated rash, hives, lip swelling, oral lesions, skin burning, flushing, and throat tightness, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: Dronabinol has been associated with seizures and seizure-like activity. Assess potential risks versus benefits in patient with a history of seizure disorder, those receiving anti-epileptic medications, or with other factors that may lower the seizure threshold. Monitor patients with a history of seizure disorder for worsened control. Discontinue dronabinol immediately in patients who develop seizures.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Substance abuse: Patients with a history of substance abuse (including marijuana or alcohol abuse) or dependence may be likely to also abuse dronabinol. Assess risk for abuse or misuse prior to treatment and monitor patients with a history of substance abuse throughout treatment. Tolerance, psychological, and physical dependence may occur with prolonged use. EEG changes consistent with withdrawal have been reported upon abrupt dechallenge of dronabinol. Sleep disturbances have been observed for several weeks after discontinuing treatment with high dronabinol doses.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Concurrent drug therapy issues</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disulfiram reaction: Dronabinol oral solution contains dehydrated alcohol, which may cause a disulfiram-like reaction (abdominal cramps, nausea, vomiting, headache, and flushing) in patients receiving disulfiram or other medications associated with this reaction (eg, metronidazole). Medications containing disulfiram or metronidazole should be discontinued at least 14 days prior to initiation of dronabinol oral solution and do not administer until 7 days following completion of dronabinol oral solution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CYP2C9 polymorphism: Clearance may be reduced and systemic effects increased in patients with CYP2C9 genetic polymorphism. Monitor for increased adverse effects in patients known to carry genetic variants associated with diminished CYP2C9 function.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Because elderly patients may be more sensitive to the neurological, psychoactive, and postural hypotensive effects of dronabinol, use with caution. Consider reduced initial doses. Elderly patients with dementia are already at increased risk for falls and fall risk may be exacerbated with dronabinol; monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric patients: Safety and efficacy of dronabinol oral solution have not been established in pediatric patients. Dronabinol oral solution contains dehydrated alcohol and propylene glycol, which should be avoided in preterm neonates and in the immediate postnatal period due to possible toxicities associated with propylene glycol. Pediatric patients may be more sensitive to CNS adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Withdrawal: May cause withdrawal symptoms upon abrupt discontinuation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299237\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2C9 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163475\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9394&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Dronabinol may enhance the CNS depressant effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Dronabinol may increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CNS Depressants: Dronabinol may enhance the CNS depressant effect of CNS Depressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the tachycardic effect of Cannabinoid-Containing Products.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Dronabinol may increase the serum concentration of CycloSPORINE (Systemic). Specifically, dronabinol may displace cyclosporine from its protein-binding sites, leading to an increased concentration of active, unbound drug. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Inhibitors (Strong): May increase the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May decrease the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disulfiram: May enhance the adverse/toxic effect of Dronabinol. Specifically, disulfiram may produce severe intolerance to the alcohol contained in the dronabinol oral solution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Dronabinol. Specifically, metronidazole may produce severe intolerance to the alcohol contained in the dronabinol oral solution.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of Dronabinol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: Cannabinoid-Containing Products may enhance the tachycardic effect of Sympathomimetics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Dronabinol may increase the serum concentration of Warfarin. Specifically, dronabinol may displace warfarin from its protein-binding sites, leading to an increased concentration of active, unbound drug. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48979079\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule: A high-fat (59 g of fat), high-calorie (~950 calories) meal resulted in a 2.9-fold increase in AUC and a 4-hour delay in the median time to peak.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: A high-fat meal (59 g of fat) or high-calorie meal (~950 calories) resulted in a 2.5-fold increase in AUC and a 5-hour delay in the median time to peak; food also decreased the C<sub>max</sub> by ~20%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13386485\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Although information related to the use of synthetic cannabinoids during pregnancy is limited, cannabinoids cross the placenta. Maternal use may increase the risk of adverse fetal/neonatal outcomes including growth restriction, low birth weight, preterm birth, and stillbirth. Some dosage forms also contain a significant amount of alcohol.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20306059\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Dronabinol is present in breast milk.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for chemotherapy-induced nausea and vomiting, the manufacturer recommends not to breastfeed during treatment and for 9 days after the last dose. When used to treat anorexia in females with HIV infection, breastfeeding should be completely avoided to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F621844\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Capsules contain sesame oil.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163480\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor heart rate and blood pressure. Monitor for CNS adverse effects, seizures (including worsened seizure control), new or worsening psychiatric symptoms, development of worsening nausea, vomiting or abdominal pain, and substance abuse behavioral profile.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163469\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dronabinol (synthetic delta-9-tetrahydrocannabinol [delta-9-THC]), an active cannabinoid and natural occurring component of <i>Cannabis sativa L.</i> (marijuana), activates cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>. Activation of the CB<sub>1</sub> receptor produces marijuana-like effects on psyche and circulation, whereas activation of the CB<sub>2</sub> receptor does not. Dronabinol has approximately equal affinity for the CB<sub>1</sub> and CB<sub>2</sub> receptors; however, efficacy is less at CB<sub>2</sub> receptors. Activation of the cannabinoid system with dronabinol causes psychological effects that can be divided into 4 groups: affective (euphoria and easy laughter); sensory (increased perception of external stimuli and of the person's own body); somatic (feeling of the body floating or sinking in the bed); and cognitive (distortion of time perception, memory lapses, difficulty in concentration). Most effects (eg, analgesia, appetite enhancement, muscle relaxation, hormonal actions) are mediated by central cannabinoid receptors (CB<sub>1</sub>), their distribution reflecting many of the medicinal benefits and adverse effects (Grotenhermen 2003).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163487\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: ~0.5 to 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peak effect: 2 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: 4 to 6 hours (psychoactive effects); &ge;24 hours (appetite stimulation)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: 90% to 95%; 10% to 20% of dose reaches systemic circulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: ~10 L/kg; dronabinol is highly lipophilic</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive first-pass hepatic primarily via microsomal hydroxylation to metabolites, some of which are active; 11-hydroxy-delta-9-tetrahydrocannabinol (11-OH-THC) is the major active metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Biphasic: Alpha: 4 to 5 hours; Terminal: 25 to 36 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: 0.5 to 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (50%, &lt;5% as unchanged drug); Urine (10% to 15%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F163490\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Dronabinol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $353.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $735.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $1,351.30</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Marinol Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (60): $786.14</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (60): $1,636.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (60): $3,004.58</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Syndros Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (30 mL): $1,278.53</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038605\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Elevat (ZA);</li>\n      <li>Marinol (BB, DE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Carley DW, Prasad B, Reid KJ, et al. Pharmacotherapy of Apnea by Cannabimimetic Enhancement, the PACE Clinical Trial: Effects of Dronabinol in Obstructive Sleep Apnea. <i>Sleep</i>. 2018;41(1).<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dronabinol-drug-information/abstract-text/29121334/pubmed\" target=\"_blank\" id=\"29121334\">29121334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. <i>Clin Pharmacokinet</i>. 2003;42(2):327-360.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dronabinol-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lohr L. Chemotherapy-induced nausea and vomiting. <i>Cancer J</i>. 2008;14(2):85-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dronabinol-drug-information/abstract-text/18391612/pubmed\" target=\"_blank\" id=\"18391612\">18391612</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marinol (dronabinol) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Syndros (dronabinol) [prescribing information]. Chandler, AZ: Insys Therapeutics Inc; May 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Treatment of Pregnant Women With HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dronabinol-drug-information/abstract-text/17555487/pubmed\" target=\"_blank\" id=\"17555487\">17555487</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9394 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16116938\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F163524\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F163507\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F163518\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F163508\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15804935\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F163509\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F48979126\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F163483\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F163466\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F163526\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27750095\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F163485\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F51128860\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F163532\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F163473\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F163488\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F163470\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299237\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F163475\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F48979079\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13386485\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20306059\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F621844\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F163480\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F163469\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F163487\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F163490\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038605\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9394|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dronabinol-patient-drug-information\" class=\"drug drug_patient\">Dronabinol: Patient drug information</a></li><li><a href=\"topic.htm?path=dronabinol-pediatric-drug-information\" class=\"drug drug_pediatric\">Dronabinol: Pediatric drug information</a></li></ul></div></div>","javascript":null}